NEKTAR THERAPEUTICS Aktie

5,54 EUR 0,7087%

Zu Ihrem Onlinebroker

kaufen verkaufen

NEKTAR THERAPEUTICS Aktienkurs : 25.05. ( 15 Min. verzögert)
5,54 € Letzter Kurs	0,71% Veränderung	5,50 € Vortag	5,54 € Eröffnungskurs

mehr Informationen

Hoch/Tief		Volumen		Geldkurs	Briefkurs
5,54 - 5,54 Tag	6,67 - 3,14 52 Wochen	0 Tag	16 Ø 52 Wochen	0,0000000 0 Stücke	0,0000000 0 Stücke

NEKTAR THERAPEUTICS Aktienkurs

Wollen Sie wissen, wie es mit dieser Aktie weitergeht?
Wir informieren Sie kostenlos.

Erhalten Sie außerdem Expertenanalysen von:
Gevestor Täglich und John Gossens Daily DAX

25.05.

Biotechnology Stocks To Watch Ahead Of ASCO 2012: Part 2

Nektar Therapeutics (NKTR): Nektar Therapeutics, a clinical-stage biopharmaceutical company, engages in developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology...
24.05.

Notable Analyst Rating Changes 05/24: (PPG) (WPI) (DUK) Upgraded; (BHI) (HGSI ...

... Outperform and $8 price target. Stephens begins Cree (Nasdaq: CREE) with an Equal Weight and $35 price target. Roth Capital starts Nektar Therapeutics (Nasdaq: NKTR) with a Buy and price ...

24.05.

Jefferies Group Analysts Begin Coverage on Nektar Therapeutics (NKTR)

Equities research analysts at Jefferies Group (NYSE: JEF) started coverage on shares of Nektar Therapeutics (NASDAQ: NKTR) in a research note issued to investors on Wednesday. The firm set a “buy” rating on the stock....
24.05.

Analysts' New Coverage for May, 24th (ACAD, AMCX, ANAD, BANC, CLSN, CNK, CREE ...

Nektar Therapeutics (NASDAQ: NKTR) is now covered by analysts at Roth Capital. They set a “buy” rating on the stock. Oaktree Capital Group LLC (NYSE: OAK) is now covered by analysts at Bank of Americ…
23.05.

Nektar rises as analyst evaluates pipeline

Nektar Therapeutics shares rose Wednesday after a Jefferies & Co. analyst started covering the stock with a "Buy" rating, pointing to its promising drug pipeline. THE SPARK: Analyst Bir…